The dual-agonist with clinical track record.
Tirzepatide is a dual-agonist* that binds both the GLP-1 and GIP receptors. It has the clearest clinical track record in the GLP-1 category, with phase 3 data across weight management and type 2 diabetes indications.
The dual-receptor mechanism is associated with appetite suppression via GLP-1 pathways and insulin sensitivity* improvements associated with GIP signaling. Clinical trials have reported weight reduction and metabolic improvement across multiple dose tiers.
Protocols are typically titrated over 12–16 weeks to allow GI adaptation*, which is the limiting factor in real-world dosing.
Every lot is independently tested before it ships. The document shown is an example of the format. The COA for your exact lot comes by email.
Get your lot's COA by email →“Cold-chain packaging was thorough, vials arrived properly stored. Lot code on the label matched the COA on the verification page exactly. Documentation is what vitalitiRX does better than competitors.”
“Ordered the 20mg size. Vial integrity was intact, seal was tamper-evident. Reconstitution instructions were clear. The structured titration guidance in the protocol notes is genuinely useful for someone new to this category.”
“Quick shipping, secure packaging. The COA was the deciding factor over Alibaba sourcing — being able to verify the lot before opening the vial is the bare minimum I expect now and most suppliers don’t offer it.”
reviews describe product + service only — purity, packaging, lot traceability, fulfilment, COA access. per health canada guidance, claims about diagnosis, treatment, or specific outcomes are edited out before publication.
